| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2015: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2014: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
|---|
| Outline of Final Research Achievements |
This project was aimed at developing potential diagnostic and therapeutic ligands for tau aggregates and other key molecules mechanistically implicated in the pathogenesis of Alzheimer’s disease and allied tauopathies. A novel radioligand, [11C]PBB3, was generated and applied to positron emission tomography (PET) of model mice and humans, providing the first demonstration of visualization of diverse tau lesions in living brains. 18F-labeled PBB3 derivatives were also produced for wider availability, and were assessed by animal PET. PET probes for deleterious microgliosis and enzymes responsible for potentiation of proinflammatory chemokines were also developed, and enabled in vivo monitoring of crosstalk between tau pathologies and neuroinflammation. A subset of PBB3 analogs was shown to suppress self-assembly of tau, indicating the capability of these chemicals as therapeutic agents.
|
